Amy Langer on Leave of Absence From NABCO After Automobile Accident

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

NEW YORK--Amy S. Langer, of the National Alliance of Breast Cancer Organizations (NABCO), has taken a leave of absence from her position as executive director, due to extensive injuries suffered in a serious car accident in upstate New York.

NEW YORK--Amy S. Langer, of the National Alliance of Breast CancerOrganizations (NABCO), has taken a leave of absence from her positionas executive director, due to extensive injuries suffered in aserious car accident in upstate New York.

The NABCO Board of Directors said in a press release that Ms.Langer is expected to recover sufficiently to return to NABCOonce her treatment and rehabilitation have concluded. During thisperiod, Betsy Gardella, NABCO's associate executive director,will assume Ms. Langer's responsibilities as acting executivedirector.

The members of NABCO's board "are deeply saddened by theaccident and express their support to Ms. Langer and her family."The staff of Oncology News International and everyone at PRR,Inc. also wish to convey their concern for Ms. Langer and offertheir support and prayers for her and her family.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.